iTeos Therapeutics, Inc.

NasdaqGM ITOS

iTeos Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024

iTeos Therapeutics, Inc. EBITDA is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

iTeos Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -88.20 M, a -126.16% change year over year.
iTeos Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 337.10 M, a 1,746.63% change year over year.
iTeos Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 18.25 M, a 163.57% change year over year.
iTeos Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -28.72 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: ITOS

iTeos Therapeutics, Inc.

CEO	Dr. Michel Detheux Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	157
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years